Immix Biopharma Announces $125M Follow‑On Offering at $11/Share

What Happened
Immix Biopharma, Inc. (IMMX) announced on September 29, 2026 that it entered into an underwriting agreement with J.P. Morgan Securities LLC to sell 11,363,637 shares of common stock at $11.00 per share in an underwritten offering. The gross proceeds equal approximately $125.0 million; the company estimates net proceeds of about $117.1 million after underwriting discounts, commissions and estimated offering expenses. The offering is expected to close on September 30, 2026, subject to customary closing conditions.

Key Details

• Underwriter: J.P. Morgan Securities LLC.
• Shares offered: 11,363,637 common shares; price per share: $11.00.
• Gross proceeds: ~$125.0 million; estimated net proceeds: ~$117.1 million.
• Offering made under shelf registration (File No. 333-292665), declared effective Jan 22, 2026; prospectus supplement dated Sept 29, 2026.
• Legal opinion regarding the validity of the shares filed as Exhibit 5.1; press release announcing pricing filed as Exhibit 99.1.

Why It Matters
This offering will raise cash for Immix Biopharma and increase the number of shares outstanding by the amount offered, which can dilute existing shareholders. The proceeds (estimated at ~$117.1M net) strengthen the company’s liquidity position; investors should review the prospectus supplement for the company’s stated intended uses of proceeds and note the offering’s close is subject to customary conditions. The filing also includes standard forward‑looking statement disclaimers.